CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
CANADA

About Us

Conference

Partner With Us

  • APAC
    • US
    • EUROPE
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    Bioinformatics & Genomics
    BioTech
    Cell and Gene Therapy
    Drug Discovery and Development
    Life Science AI
    Next-Generation Sequencing
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    CDMO
    Cosmetic
    CRO
    Life Science Testing And Compliance
    Supplement Manufacturing
  • Business Services
    Life Science Consulting
    Life Sciences Marketing and Communication
  • Leadership Perspectives
  • Innovation Insights
  • News
  • Magazines
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

A featured contribution from Leadership Perspectives: a curated forum reserved for leaders nominated by our subscribers and vetted by our Life Sciences Review Advisory Board.

Oxford PharmaGenesis

Kim Wager, Scientific Director

Machine-Learning-Generated Insights from Health Data: Promise of Natural Language Processing

Kim Wager

Kim Wager

Scientific Insights Advisor

Have you ever wondered what can cause a publication to ‘go viral’? Natural language processing (NLP) enabled us to analyse the growth of a very popular scientific journal article (a recent clinical trial of dostarlimab) by summarizing within minutes the thousand news articles that mentioned it. We found that these articles used terms of exaggeration (e.g. ‘revolutionary’, ‘unprecedented’, ‘scientific miracle’), which suggests that over-inflating results in news reporting may be a method to achieve popularity (a strategy we would not recommend!). The timely analysis of the vast quantity of these articles was made possible by NLP, a technique that is well suited to processing large volumes of text.


Several million scientific publications are now added to PubMed each year, compared with about 300 000 in 1980. The volume of health-related text (including publications, but also electronic health records) has grown exponentially with time; the resulting volume can only be fully and efficiently analysed with the help of automation. NLP helps pharmaceutical companies and other researchers to derive insights from this flood of healthrelated information, ultimately benefiting patients.


Considerable progress has been achieved in NLP in the last thirty years. Early approaches to NLP, which focused on the logical application of rules, failed to capture linguistic complexity and have proven limited in their usefulness. Using artificial neural networks, modern NLP performed well at ‘understanding’ language by creating abstract representations of words and their contexts. This has opened up applications for healthcare and medical and pharmaceutical research.


Exciting Applications of NLP for Health


NLP can summarize documents, focusing on the topic (topic modelling) or the opinion and emotional tone (sentiment analysis). Topic modelling can quickly condense themes in the published research on a therapy area. This application can inform the publication strategies of research institutions and pharmaceutical companies by enabling them to choose whether to contribute to common themes or to address potential literature gaps. Sentiment analysis can determine whether a publication was cited by others to confirm or to refute it, or for information only; such information augments a simple citation count to enable better judgment on publication reliability.


NLP can also be used to extract data from publications, such as individual entities (via a method called named entity recognition) or relationships between entities (through relationship extraction). For example, named-entity recognition could extract the clinical outcome of a trial treatment arm, and relationship extraction could link this outcome to the drug and dosage used in that arm. This may accelerate the data extraction phase of systematic literature reviews, which are the cornerstone of evidence-based medical decision-making.


Aside from publications and electronic health records, NLP tools can also analyse non-traditional text sources such as social media posts to monitor the experiences of patients with disease and treatment.


Avoiding the Pitfalls of Biomedical NLP


The successful biomedical application of NLP requires expertise in both NLP and medicine to ensure that we ask the right questions and interpret the answers correctly; however, such expertise is scarce. Successful implementation of NLP in the biomedical sphere may require the services of consultants who have the interdisciplinary knowledge to understand, implement, and communicate biomedical NLP findings.


In particular, the interpretation of NLP-derived outputs needs special care. Modern NLP approaches require training data from which correlations are first derived and then extrapolated onto new data to make predictions. Consider the example of a tool trained to extract drug dosage from clinical trial publications. If drug dosages are always presented using one unit (e.g. mg) in training data, NLP might be unable to extract the dosage presented with another unit (e.g. µg/mm2). This reliance on good training data limits the power of NLP; if the training data contain mistakes, these will be reproduced in NLP-derived outputs. Awareness of these limits by interdisciplinary experts enables appropriate interpretation and communication of results, building trust in the true potential of NLP.


A Promising Future for Biomedical NLP


Aside from publications and electronic health records, NLP tools can also analyse non-traditional text sources such as social media posts to monitor the experiences of patients with disease and treatment. For example, social media listening can be used to inform drug development by evaluating the impact of chronic disease on the quality of life of patients. A 2019 study used NLP to identify and evaluate social media accounts of life with dry eye disease, which yielded insights into the needs of patients that have yet to be met by the pharmaceutical industry.


Pharmaceutical companies may also find new opportunities for NLP application. Information derived from NLP can be augmented with existing biological and clinical databases (e.g. UniProt for protein information, ClinicalTrials.gov for clinical trial data) to find new relationships between data. Such relationships could link an existing drug with a novel therapy area, which may constitute a repurposing opportunity.


In the last few years, considerable progress has been made in the field of NLP and we are now seeing powerful medical applications emerging. The biomedical opportunities offered by NLP are vast; to stay ahead, pharmaceutical companies should embrace NLP and benefit from the support of interdisciplinary experts to help avoid potential pitfalls.


The articles from these contributors are based on their personal expertise and viewpoints, and do not necessarily reflect the opinions of their employers or affiliated organizations.

Editorial Lens

Life sciences leaders must treat biomedical NLP as a strategic insight capability that can turn expanding health data into faster evidence generation and better research judgment.This perspective underscores why interdisciplinary expertise, careful interpretation and trusted training data now determine whether machine-learning outputs can support credible pharmaceutical decision-making.

The Leadership Perspectives forum brings together voices shaping the future of life sciences. It features leaders who are advancing change across the industry through strategic leadership and applied insight.
EDITOR'S CHOICE
  • Willis Towers Watson

    ICON [NASDAQ: ICLR]

    The Significant Increase in Demand for Clinical Research Associates (CRAs)

    Helen Yeardley, Executive Vice President, ICON [NASDAQ: ICLR]

  • Willis Towers Watson

    PacBio [NASDAQ: PACB]

    The Talent - Culture Continuum: How to Manage an Innovation Culture Amid Growth and Change

    Alvin Hom, Head of Global Talent Acquisition, PacBio [NASDAQ: PACB]

  • Willis Towers Watson

    Repligen Corp [NASDAQ: RGEN]

    Gene Therapy-Therapeutic Viral Vectors; Manufacturing, Challenges, and Innovation

    Rachel Legmann, PhD, Senior Director of Technology, Gene Therapy, Repligen Corp

  • Willis Towers Watson

    Ionis Pharmaceuticals [NASDAQ: IONS]

    Bridging the Diversity Divide

    Victoria Sanjurjo, Medical Director, Clinical Development, Ionis Pharmaceuticals, Inc [NASDAQ: IONS]

Life Sciences Review APAC
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review APAC. All rights reserved. Headquartered in Fort Lauderdale, FL, USA.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreviewapac.com/leadership-perspective/machinelearninggenerated-insights-from-health-data-promise-of-natural-language-processing-nwid-3388.html